Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q4 2017 · 10-K
Revenue$945.00K$945.00K−14.3% vs Q4 2016 Net Income-$71.93M-$71.93MN/M vs Q4 2016 EPS, diluted—
Gross Profitderived$945,000−14.5% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Income
Operating Cash Flowderived-$5,675,000N/M Free Cash Flowderived-$6,071,000— Margins · derivedGross margin100.0%−0.2 pt vs Q4 2016
Operating margin-1012.0%+8.3 pt vs Q4 2016
Net margin-7612.1%−7163.7 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 15, 2018 · 74 d after period end